Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02551159 |
| Title | Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN |
| Acronym | KESTREL |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | AstraZeneca |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | SVK | ROU | POL | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT |